Diagnosis and risk stratification
An algorithmic approach to guide diagnosis
Our updated approach to fluorescence in-situ hybridization (FISH) testing takes into account the fact that multiple myeloma is increasingly recognized as more than one disease, and is characterized by cytogenetic, molecular, and proliferative heterogeneity. While novel agents and combinations are rapidly redefining the treatment paradigm, patient outcomes vary based on risk stratification.
Created in conjunction with Mayo Clinic’s multiple myeloma clinical practice, mSMART uses flow cytometry, FISH, and the latest consensus to determine a patient’s genetic risk of developing multiple myeloma. This approach better informs individualized treatment plans and provides clinicians with a comprehensive and correlated patient profile.
Comprehensive testing, simplified
In addition to mSmart evaluation, Mayo Clinic Laboratories now offers comprehensive FISH testing for diagnosis and risk stratification of multiple myeloma. Our approach to fluorescence in situ hybridization (FISH)testing is designed to simplify the ordering process by providing diagnostic panels that include all appropriate genes.
Updated testing algorithms for plasma cell proliferative disorders
Xinjie Xu, Ph.D., co-director of Mayo Clinic's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in-situ hybridization (FISH) panels, rather than chromosome studies.
A comparison of testing approaches
The group's mission is to present the state-of-the-art approach to management of these plasma cells disorders including myeloma, amyloidosis, and Waldenstrom macroglobulinemia. Views expressed here are opinions of a group of experts, based on best available evidence.